Health Care·Pharmaceuticals·$119.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.45 | N/A | +8.96% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.45 | N/A | +8.96% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed confidence in the company's strategic direction. They noted the importance of their product pipeline in driving future growth.
Management highlighted strong performance in key therapeutic areas.
They emphasized ongoing commitment to innovation and pipeline development.
Bristol Myers Squibb's earnings report showed a positive surprise in EPS, which contributed to a 2.15% increase in stock price. The management's focus on their product pipeline and strong performance in key areas suggests a commitment to future growth. However, the lack of revenue data and guidance leaves some uncertainty for investors.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ASBURY AUTOMOTIVE GR
Oct 21, 2014